Search results for 8353

Showing 12 results out of 62

×

Species

Types

Compartments

Search properties

Species

Types

Compartments

Search properties

Protein (10 results from a total of 60)

Identifier: R-HSA-8943829
Species: Homo sapiens
Compartment: cytosol
Primary external reference: UniProt: P68431
Identifier: R-HSA-4568761
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-212070
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-977570
Species: Homo sapiens
Compartment: extracellular region
Primary external reference: UniProt: H3C1: P68431
Identifier: R-HSA-5244806
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: H3C1: P68431
Identifier: R-HSA-5244801
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-5244529
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-5229059
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-5246534
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431
Identifier: R-HSA-5246530
Species: Homo sapiens
Compartment: nucleoplasm
Primary external reference: UniProt: P68431

ChemicalDrug (1 results from a total of 1)

Identifier: R-ALL-9657557
Compartment: cytosol

Reaction (1 results from a total of 1)

Identifier: R-HSA-9657603
Species: Homo sapiens
Compartment: plasma membrane, cytosol
A number of 'dual mechanism' MAPK inhibitors are in preclinical or clinical trials (reviewed in Roskoski, 2019). Dual mechanism inhibitors, including the ATP-competitive inhibitors SCH772984 and MK-8353, bind to the unphosphorylated MAPK and prevent both its own kinase activity and its phosphorylation by MAP2Ks (Morris et al, 2013; Deng et al 2014; Chaikuad et al, 2014; Boga et al, 2018; Moschos et al, 2019; reviewed in Samatar and Poulikakos, 2014). MAPK inhibitors offer the potential to mitigate the development of resistance to RAF and MAP2K inhibitors, which often involves reactivation of MAPK-dependent signaling. As a result, MAPK inhibitors are frequently used in combination with RAF and MAP2K-directed therapeutics (reviewed in Samatar and Poulikakos, 2014; Roskoski, 2019).
Cite Us!